• Molecular NameAtazanavir
  • Synonymatazanavir; Atazanavir sulfate; ATV; ATZ; BMS-232632
  • Weight704.869
  • Drugbank_IDDB01072
  • ACS_NO198904-31-3
  • Show 2D model
  • LogP (experiment)4.25
  • LogP (predicted, AB/LogP v2.0)4.15
  • pkaN/A
  • LogD (pH=7, predicted)4.14
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-5.54
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors5
  • No.of HBond Acceptors13
  • No.of Rotatable Bonds18
  • TPSA171.22
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV).
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability64.0
  • Protein binding86.0
  • Volume of distribution (VD)1.6~2.7 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP3A4-mediated)
  • Half life7.9 h
  • ExcretionFecal and renal
  • Urinary Excretion7
  • Clerance3.4 ml/min/kg
  • ToxicitySelected treatment-emergent adverse Eventsa of Moderate or Severe Intensity Reported in ≥2% of Adult Treatment-Naive Patientsb
  • LD50 (rat)N/A
  • LD50 (mouse)N/A